Now supporting both Illumina short-read and Oxford Nanopore long-read sequencing platforms, the NGD200 is the industry's first to enable WGS-based hospital transmission detection.
CAMBRIDGE, MA / ACCESS Newswire / June 8, 2026 / NGD Infection Prevention announced today that its automated sequence-based infection transmission detection system is now compatible with Oxford Nanopore long-read sequencing. The automation, throughput and simplicity of use of the NGD200 sample preparation robotic system and NGD's integrated automated bioinformatics are now all available for Nanopore sequencing.
Infection prevention teams increasingly recognize that comparing the whole genome sequence (WGS) of infections is the only way to catch transmission as more than 90% of bacterial transmission in hospitals remaining undetected despite diligent efforts.[1],[2] The use of sequencing was until recently impractical, requiring specialized expertise and often only available at unpalatable costs - the NGD200 was designed to close that gap. A low-skill technician loads bacterial samples, prepares reagents, starts the run, and walks away. The NGD200 performs lysis, extraction, normalization, library construction, pooling, and size selection in a single automated run. Four hours later the system delivers 48 barcoded, sequence-ready libraries ready to be sequenced.
"Hospital Infection Prevention leaders increasingly realize that sequencing is the only way to detect transmission - the challenge has always been that no practical path to get there existed. The NGD200 system was designed from the ground up to operate inside the hospital microbiology lab, with no specialist expertise. We can now put a compact PromethION on the bench next to an NGD200, link to our automated bioinformatics, and a low skill lab with <6' of bench, that has not done any sequencing in the past, can transform infection control in their hospital."- Paul A. Rhodes, PhD, CEO and Founder, NGD Infection Prevention |
Actionable sequencing-based infection relatedness results flow automatically into NGD EpiAssist, NGD's HIPAA-compliant bioinformatics and root-cause determination platform. EpiAssist rapidly determines whether newly sequenced samples are identical (e.g. within 10 SNPs in the entire core genome) to any prior isolates - enabling infection prevention teams to identify outbreaks at the 2nd patients, intervene early, before a single transmission event becomes a larger outbreak. Isolates available in the morning are transformed into relatedness and infection transmission results the next morning, populating an intuitive interface that creates the map of the time-and-place history of each patient, including ward location, procedures and caregivers, identifying and ranking potentially causal linkages, dramatically reducing the time required for outbreak investigation and root cause identification. Now with the expansion to Nanopore sequencing, NGD's system can deliver plasmid copy number and identity, further insights benefiting the work of the Infection Prevention team.
The NGD200 is available as part of NGD's complete, on-premises turnkey service - encompassing installation, structured onboarding, and dedicated ongoing technical and operational support. The full NGD solution, from automated sample preparation through sequencing, bioinformatics, and actionable IP team reporting, makes routine, real-time infection transmission detection operationally and economically achievable in the hospital setting for the first time.
About NGD Infection Prevention
NGD Infection Prevention provides a fully automated, end-to-end whole-genome sequencing platform and bioinformatics pipeline, enabling hospitals to detect and prevent transmission in real-time. The NGD200 system processes 48 bacterial samples with minimal low-skill hands-on time, while NGD EpiAssist automates bioinformatics as well as root cause determination, delivering actionable reports overnight at the low per-sample cost needed for broad adoption. The company has a laboratory in Cambridge MA, a business office in Boston, and a subsidiary in Israel.
Media Contact: Nicole Brokob
Director of Marketing & Communications, NGD
nbrokob@ngdinfectionprevention.com
Press Inquiries: press@nextgen-dx.com
[1] Coll, et al. Science Translational Medicine, 2017
[2] Sunderman, et al. Clinical Infectious Diseases, 2022
SOURCE: Next Gen Diagnostics
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/ngd-infection-prevention-launches-the-ngd200-the-first-automated-bacterial-sample-pre-1173871
